ATTD-ASIA: A Collaborative Innovation Platform for Diabetes Care Technologies
The Advanced Technologies & Treatments for Diabetes (ATTD) Conference is one of the most influential global conferences in the field of diabetes technology.
ATTD offers a world-class platform for clinicians, scientists, and innovative global companies to exchange knowledge, showcase new technologies, and share insights at the forefront of diabetes treatment. The conference plays a vital role in advancing diabetes care technologies and accelerating their clinical adoption worldwide.
ATTD-ASIA was successfully launched in 2024, and the 2025 conference (ATTD-ASIA 2025) continues to lead advancements in diabetes care across the Asia-Pacific region. The conference focuses on cutting-edge technologies including AI- and big-data-based decision support systems, closed-loop systems and algorithms, artificial pancreas solutions, insulin pumps, and continuous glucose sensing technologies.
ATTD-ASIA 2025 will bring together 750 clinicians, researchers, investors, payers, and regulatory professionals from 48 countries, along with more than 60 world-renowned experts and leading diabetes technology companies such as Roche, Medtronic, Abbott, and Dexcom. With over 170 keynote sessions and discussions on innovative diabetes technologies and treatments, the conference will serve as a comprehensive platform for technical exchange and cross-sector collaboration.
Teljane Medical’s Global Strategy: Advancing with World-Leading Innovation Strength
Teljane Medical Technology (Suzhou) Co., Ltd. is an innovative company dedicated to developing internationally advanced Continuous Glucose Monitoring System (CGMS) products. Founded in July 2021 and headquartered in Well Lead Medical Innovation Park in Suzhou Industrial Park, the company is led by seasoned experts from multinational medical device companies and focuses on the full lifecycle of CGMS development, manufacturing, and commercialization.
More than 50% of our team consists of R&D engineers, many of whom hold master’s or doctoral degrees. The team has strong expertise in electrochemical sensing, signal processing and algorithms, and Micro-Electro-Mechanical Systems (MEMS). A major breakthrough has been achieved in core sensor technology — the independently developed TS-1 Super Biosensor, which forms the foundation for next-generation performance enhancements in CGMS products.
In terms of technological innovation, Teljane Medical has filed 34 patents as of 2025, covering core components including biosensors, electronic transmitters, and applicators. These innovations address key pain points in traditional CGMS technology — sensitivity, stability, and battery life — from the foundational technical level. Our first CGMS product is expected to obtain CE certification in 2025 and is already in the preparation phase for large-scale manufacturing, building a solid foundation for our global commercialization strategy.
Powered by the revolutionary TS-1 Super Biosensor technology, Teljane Medical is driving a new wave of innovation in diabetes management — advancing glucose monitoring solutions toward greater accuracy, comfort, and patient-centric design.
Sincerely Inviting You to Join Us in Singapore — A Global Hub Where Innovation Meets Culture
According to the latest data released by the International Diabetes Federation (IDF) in 2025, the global prevalence of diabetes has reached 11.1%. China, India, and the United States are the top three countries with the largest number of people living with diabetes. With such a rapidly growing patient population, the adoption of new technologies and innovative therapies is becoming essential to improve quality of life.
Since its establishment, Teljane Medical has been committed to a patient-centric mission — delivering convenient and accurate CGMS solutions for more than 500 million people with diabetes worldwide. We aim to reduce the burden of glucose monitoring and enable individuals to live with greater ease and confidence. As a young and fast-growing company, we are driven to demonstrate that Chinese innovation not only keeps pace with global advances but is positioned to shape the future standards of the industry.
In 2025, Teljane Medical will make its debut on the international stage of medical technology innovation at ATTD-ASIA 2025, joining leading global players such as Abbott and Dexcom. We will proudly showcase our first-generation CGMS innovation at the industry exhibition. We sincerely invite you to visit our booth, exchange ideas, and witness the breakthrough of Chinese CGMS technology together!
Conference Information
- Date: December 9–11, 2025
- Venue: Suntec Singapore Convention & Exhibition Centre 1 Raffles Boulevard, Singapore 039593
- Booth No.: #10
- Focus: Showcasing and discussing Teljane Medical’s innovative CGMS product portfolio
Whether you are a potential business partner, a clinician exploring innovative solutions, or an investor focused on the future of medical technology, Teljane Medical looks forward to meeting you at ATTD-ASIA 2025.
Teljane Medical WeChat Official Account QR Code
